Payment overview · 2025
General Payments
$391.60
24 reported records · 11 companies
Healthcare provider profile · identity verified
Michael Delaney, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GRAND RAPIDS, MI · NPI 1174905905
Verified facts
What the public records show
CMS Open Payments records show Michael Delaney, M.D. received $391.60 in general payments during 2025 across 24 reported records.
ABBVIE INC. accounted for 38.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Nurtec Odt, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $151.46 | 38.7% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.89 | 12.5% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $29.05 | 7.4% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $27.95 | 7.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $26.72 | 6.8% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $23.42 | 6.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.49 | 4.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.57 | 4.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.55 | 4.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.74 | 4.3% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $13.76 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $377.84 | 23 |
| Education | $13.76 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $104.92 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $73.41 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $48.89 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $29.05 | 1 | 2025 |
Source payment records
|
|||||
| Epclusa Normalized: epclusa |
Drug | Gilead Sciences, Inc. | $27.95 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $26.72 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $23.42 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $22.55 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.74 | 1 | 2025 |
Source payment records
|
|||||
| EOHILIA Normalized: eohilia |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 122 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
40 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
122 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
190 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
65 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
175 | 39 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 638 | 198 |
| Lisinopril | Lisinopril | 464 | 130 |
| Omeprazole | Omeprazole | 356 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 331 | 97 |
| Levothyroxine Sodium | Levothyroxine Sodium | 274 | 79 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 262 | 49 |
| Prednisone | Prednisone | 249 | 120 |
| Metformin Hcl | Metformin Hcl | 244 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 232 | 70 |
| Losartan Potassium | Losartan Potassium | 207 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 197 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 197 | 67 |
| Mounjaro | Tirzepatide | 190 | 39 |
| Eliquis | Apixaban | 175 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 170 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 160 | 53 |
| Simvastatin | Simvastatin | 152 | 39 |
| Carvedilol | Carvedilol | 146 | 44 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 139 | 51 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 139 | 24 |
| Furosemide | Furosemide | 138 | 53 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 137 | 36 |
| Gabapentin | Gabapentin | 136 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 134 | 76 |
| Alprazolam | Alprazolam | 133 | 27 |
| Jardiance | Empagliflozin | 122 | 34 |
| Trazodone Hcl | Trazodone Hcl | 120 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 117 | 47 |
| Potassium Chloride | Potassium Chloride | 116 | 42 |
| Allopurinol | Allopurinol | 106 | 31 |
| Pregabalin | Pregabalin | 100 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 96 | 29 |
| Sertraline Hcl | Sertraline Hcl | 87 | 25 |
| Tramadol Hcl | Tramadol Hcl | 86 | 28 |
| Famotidine | Famotidine | 84 | 33 |
| Metformin Hcl Er | Metformin Hcl | 83 | 20 |
| Bupropion Xl | Bupropion Hcl | 77 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 77 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 77 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 71 | 25 |
| Chlorthalidone | Chlorthalidone | 67 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 29 |
| Azithromycin | Azithromycin | 66 | 51 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 66 | 28 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 65 | 52 |
| Trulicity | Dulaglutide | 65 | 19 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 63 | 22 |
| Finasteride | Finasteride | 63 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 63 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 59 | 18 |
| Meloxicam | Meloxicam | 56 | 23 |
| Spironolactone | Spironolactone | 56 | 14 |
| Buspirone Hcl | Buspirone Hcl | 53 | 14 |
| Bumetanide | Bumetanide | 52 | 16 |
| Cephalexin | Cephalexin | 52 | 42 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | 18 |
| Montelukast Sodium | Montelukast Sodium | 49 | 14 |
| Ibuprofen | Ibuprofen | 48 | 18 |
| Morphine Sulfate Er | Morphine Sulfate | 47 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 46 | 16 |
| Tramadol Hcl Er | Tramadol Hcl | 46 | suppressed |
| Xarelto | Rivaroxaban | 45 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 42 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | 12 |
| Propranolol Hcl | Propranolol Hcl | 41 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 41 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 40 | 12 |
| Topiramate | Topiramate | 40 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 38 | 17 |
| Torsemide | Torsemide | 37 | 13 |
| Spiriva Respimat | Tiotropium Bromide | 36 | 12 |
| Nitroglycerin | Nitroglycerin | 35 | 29 |
| Risperidone | Risperidone | 35 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 33 | 23 |
| Lorazepam | Lorazepam | 31 | 11 |
| Valacyclovir | Valacyclovir Hcl | 31 | 15 |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 29 | suppressed |
| Roflumilast | Roflumilast | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 22 |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 21 |
| Estradiol | Estradiol | 28 | suppressed |
| Sucralfate | Sucralfate | 28 | 13 |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 25 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 20 |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Ozempic | Semaglutide | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 17 |
| Celecoxib | Celecoxib | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | 18 |
| Olanzapine | Olanzapine | 19 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | suppressed |
| Clobazam | Clobazam | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 13 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $391.60 · 24 records | ABBVIE INC. | BREZTRI, CAPLYTA, EOHILIA, ESPRIT, Epclusa, JARDIANCE, JOURNAVX, NURTEC ODT, Ozempic, QULIPTA, REXULTI, Rybelsus, UBRELVY, VRAYLAR | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error